Pancreatic cancer

Published on November 30, 2016 Updated on December 23, 2020   47 min

A selection of talks on Cancer

Please wait while the transcript is being prepared...
Hi, I'm Dr. Randall Brand. I'm Professor of Medicine at the University of Pittsburgh Medical Center in the Division of Gastroenterology, Hepatology and Nutrition. It's my pleasure to discuss with you today on the topic of pancreatic cancer.
My talk today will review some general background on pancreatic cancer, highlighting risk factors for the disease, how it clinically presents, some of the common diagnostic modalities used in pancreatic cancer, review pancreatic cystic lesions, the staging of the disease, treatment, and then some of our current needs for the disease.
Worldwide pancreatic cancer causes over 300,000 deaths. In the United States, it's estimated that there will be over 53,000 new patients diagnosed with pancreatic cancer, with majority of these dying with a predicted almost 42,000 deaths. In the United States, there's about 1.4% lifetime risk of developing pancreatic cancer, and it's currently the third leading cause of cancer-related mortality in the United States. The vast majority of the tumors are adenocarcinomas accounting for over 90% with other types including neuroendocrine, acinar, and lymphomas. My talk today will be focusing on adenocarcinomas.
As you can see here, this is a diagram showing five-year survival rates for major digestive diseases. This is colon cancer where we've had significant improvement since 1975 with rates increasing almost 20%. This is pancreatic cancer, and you can see since 1975 that we've only made modest gains, and we're still under 10% for five-year survival. This is compared to several of the other GI malignancies where they despite still four or five-year survival rates, they're getting closer to 20%.